Moving beyond rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone for diffuse large B-cell lymphoma.

Abstract

Diffuse large B-cell lymphoma (DLBCL) is the most common B-cell non-Hodgkin lymphoma (NHL). While the de facto treatment standard R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) is curative in most cases, it is ineffective for a significant proportion of patients, particularly those with intermediate and high-risk disease. Efforts to improve upon the results of R-CHOP have principally explored dose intensification of chemotherapy and resulted in considerable additive toxicity without clear benefit. DLBCL is not a uniform disease, however, and can be dissected into distinct molecular subtypes by gene expression profiling. These subtypes are characterized by distinct oncogenic mechanisms of activation and addictions to aberrant intracellular signaling pathways. Novel therapeutic agents that target these pathway addictions are emerging, and may have specific activity within molecular subtypes of DLBCL. To move beyond R-CHOP for all patients with DLBCL, targeted therapies added to the most effective chemotherapy platforms must be studied within the context of molecularly defined subsets.

• Authors: Mark Roschewski, Kieron Dunleavy, Wyndham H Wilson
• Journal: Leukemia & lymphoma (Leuk Lymphoma) Vol. 55 Issue 11 Pg. 2428-37 (Nov 2014) ISSN: 1029-2403 [Electronic] United States
• PMID: 24438195 (Publication Type: Journal Article, Research Support, N.I.H., Intramural, Review)

Chemical References

• Antibodies, Monoclonal, Murine-Derived
• Rituximab
• Vincristine
• Doxorubicin
• Cyclophosphamide
• Prednisone

Topics

• Antibodies, Monoclonal, Murine-Derived (administration & dosage)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Cyclophosphamide (administration & dosage)
• Doxorubicin (administration & dosage)
• Humans
• Lymphoma, Large B-Cell, Diffuse (drug therapy)
• Molecular Targeted Therapy (methods, trends)
• Prednisone (administration & dosage)
• Rituximab
• Treatment Outcome
• Vincristine (administration & dosage)